Literature DB >> 19046006

Risk factors for development of neurologic disease after experimental exposure to equine herpesvirus-1 in horses.

George P Allen1.   

Abstract

OBJECTIVE: To identify risk factors associated with development of clinical neurologic signs in horses exposed to equine herpesvirus-1 (EHV-1). ANIMALS: 36 adult horses. PROCEDURES: Blood samples collected before and after challenge inoculation with nonneuropathogenic or neuropathogenic EHV-1 were analyzed for leukocyte-associated viremia, serum neutralizing antibody, and EHV-1-specific cytotoxic T-lymphocyte precursors (CTLPs). Associations between variables and neurologic disease and correlations between age category or breed and development of neurologic disease were examined.
RESULTS: 9 horses developed CNS signs (ataxia, hind limb paresis or paralysis, bladder atony, or recumbency). Neurologic deficits were correlated with infection by a neuropathogenic strain of EHV-1, age>20 years, high postexposure viremic load, and low preexposure concentration of CTLPs. No significant correlations were observed between preinfection titers or horse breed and postinfection development of neurologic signs. CONCLUSIONS AND CLINICAL RELEVANCE: Horses with high concentrations of preexisting CTLPs, regardless of age, strain of virus, or titer, were more likely to control the magnitude of postinfection leukocyte-associated viremia and subsequent development of neurologic disease; therefore, CTLPs appear to be a critical requirement for protective immunity against EHV-1-induced myeloencephalopathy. The importance of achieving immunity related to high concentrations of vaccine-induced CTLPs in horses at high risk for exposure to neuropathogenic strains of EHV-1 is indicated.

Entities:  

Mesh:

Year:  2008        PMID: 19046006     DOI: 10.2460/ajvr.69.12.1595

Source DB:  PubMed          Journal:  Am J Vet Res        ISSN: 0002-9645            Impact factor:   1.156


  21 in total

1.  Loop-mediated isothermal amplification-fluorescent loop primer assay for the genotyping of a single nucleotide polymorphism at position 2254 in the viral DNA polymerase gene of equid alphaherpesvirus 1.

Authors:  Koji Tsujimura; Hiroshi Bannai; Manabu Nemoto; Hiroshi Kokado
Journal:  J Vet Diagn Invest       Date:  2019-06-06       Impact factor: 1.279

2.  An Equine Herpesvirus Type 1 (EHV-1) Ab4 Open Reading Frame 2 Deletion Mutant Provides Immunity and Protection from EHV-1 Infection and Disease.

Authors:  Christiane L Schnabel; Susanna Babasyan; Alicia Rollins; Heather Freer; Christine L Wimer; Gillian A Perkins; Fahad Raza; Nikolaus Osterrieder; Bettina Wagner
Journal:  J Virol       Date:  2019-10-29       Impact factor: 5.103

3.  The common equine class I molecule Eqca-1*00101 (ELA-A3.1) is characterized by narrow peptide binding and T cell epitope repertoires.

Authors:  Tobias Bergmann; Carrie Moore; John Sidney; Donald Miller; Rebecca Tallmadge; Rebecca M Harman; Carla Oseroff; Amanda Wriston; Jeffrey Shabanowitz; Donald F Hunt; Nikolaus Osterrieder; Bjoern Peters; Douglas F Antczak; Alessandro Sette
Journal:  Immunogenetics       Date:  2015-09-23       Impact factor: 2.846

4.  Assessment of listing and categorisation of animal diseases within the framework of the Animal Health Law (Regulation (EU) No 2016/429): infection with Equine Herpesvirus-1.

Authors:  Søren Saxmose Nielsen; Julio Alvarez; Dominique Joseph Bicout; Paolo Calistri; Elisabetta Canali; Julian Ashley Drewe; Bruno Garin-Bastuji; José Luis Gonzales Rojas; Christian Gortázar; Mette Herskin; Virginie Michel; Miguel Ángel Miranda Chueca; Helen Clare Roberts; Barbara Padalino; Paolo Pasquali; Hans Spoolder; Karl Ståhl; Antonio Velarde Calvo; Arvo Viltrop; Christoph Winckler; Andrea Carvelli; Romain Paillot; Alessandro Broglia; Lisa Kohnle; Francesca Baldinelli; Yves Van der Stede
Journal:  EFSA J       Date:  2022-01-12

5.  Evaluation of immune responses following infection of ponies with an EHV-1 ORF1/2 deletion mutant.

Authors:  Gisela Soboll Hussey; Stephen B Hussey; Bettina Wagner; David W Horohov; Gerlinde R Van de Walle; Nikolaus Osterrieder; Lutz S Goehring; Sangeeta Rao; David P Lunn
Journal:  Vet Res       Date:  2011-02-07       Impact factor: 3.683

6.  Detection of the neuropathogenic variant of equine herpesvirus 1 associated with abortions in mares in Poland.

Authors:  Karol Stasiak; Jerzy Rola; Gabor Ploszay; Wojciech Socha; Jan F Zmudzinski
Journal:  BMC Vet Res       Date:  2015-05-01       Impact factor: 2.741

7.  Effect of a Histone Demethylase Inhibitor on Equine Herpesvirus-1 Activity In Vitro.

Authors:  Rebecca L Tallmadge; Emilija Žygelytė; Gerlinde R Van de Walle; Thomas M Kristie; M Julia B Felippe
Journal:  Front Vet Sci       Date:  2018-03-12

8.  A Live-Attenuated Equine Influenza Vaccine Stimulates Innate Immunity in Equine Respiratory Epithelial Cell Cultures That Could Provide Protection From Equine Herpesvirus 1.

Authors:  Lila M Zarski; Wendy E Vaala; D Craig Barnett; Fairfield T Bain; Gisela Soboll Hussey
Journal:  Front Vet Sci       Date:  2021-06-10

9.  Clinical observations and management of a severe equine herpesvirus type 1 outbreak with abortion and encephalomyelitis.

Authors:  Jasmin Walter; Christoph Seeh; Kerstin Fey; Ulrich Bleul; Nikolaus Osterrieder
Journal:  Acta Vet Scand       Date:  2013-03-05       Impact factor: 1.695

10.  Experimental infection with equine herpesvirus type 1 (EHV-1) induces chorioretinal lesions.

Authors:  Gisela Soboll Hussey; Lutz S Goehring; David P Lunn; Stephen B Hussey; Teng Huang; Nikolaus Osterrieder; Cynthia Powell; Jesse Hand; Carine Holz; Josh Slater
Journal:  Vet Res       Date:  2013-12-05       Impact factor: 3.683

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.